CO2018005141A2 - Proceso para preparar una formulación en polvo seco que comprende un anticolinérgico, un corticosteroide y un beta-adrenérgico - Google Patents
Proceso para preparar una formulación en polvo seco que comprende un anticolinérgico, un corticosteroide y un beta-adrenérgicoInfo
- Publication number
- CO2018005141A2 CO2018005141A2 CONC2018/0005141A CO2018005141A CO2018005141A2 CO 2018005141 A2 CO2018005141 A2 CO 2018005141A2 CO 2018005141 A CO2018005141 A CO 2018005141A CO 2018005141 A2 CO2018005141 A2 CO 2018005141A2
- Authority
- CO
- Colombia
- Prior art keywords
- anticholinergic
- corticosteroid
- dry powder
- powder formulation
- adrenergic
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
- A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/194—Carboxylic acids, e.g. valproic acid having two or more carboxyl groups, e.g. succinic, maleic or phthalic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
- A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
- A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1617—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1617—Organic compounds, e.g. phospholipids, fats
- A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/08—Bronchodilators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Pulmonology (AREA)
- Molecular Biology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Biophysics (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Pain & Pain Management (AREA)
- Otolaryngology (AREA)
- Biochemistry (AREA)
- Rheumatology (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medical Preparation Storing Or Oral Administration Devices (AREA)
Abstract
La invención se relaciona con una formulación en polvo seco para inhalación que comprende una combinación de un anticolinérgico, un agonista de beta2-adrenoceptor de acción prolongada, y un corticosteroide, y con un proceso para la preparación de la misma.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP15194660 | 2015-11-16 | ||
PCT/EP2016/077558 WO2017085004A1 (en) | 2015-11-16 | 2016-11-14 | A process for preparing a dry powder formulation comprising an anticholinergic, a corticosteroid and a beta-adrenergic |
Publications (1)
Publication Number | Publication Date |
---|---|
CO2018005141A2 true CO2018005141A2 (es) | 2018-09-28 |
Family
ID=54548062
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CONC2018/0005141A CO2018005141A2 (es) | 2015-11-16 | 2018-05-16 | Proceso para preparar una formulación en polvo seco que comprende un anticolinérgico, un corticosteroide y un beta-adrenérgico |
Country Status (36)
Country | Link |
---|---|
US (4) | US10086004B2 (es) |
EP (3) | EP3620176B1 (es) |
JP (1) | JP6963548B2 (es) |
KR (1) | KR20180082443A (es) |
CN (1) | CN108289962B (es) |
AR (1) | AR106688A1 (es) |
AU (1) | AU2016356858B2 (es) |
CA (1) | CA3005290A1 (es) |
CL (1) | CL2018001298A1 (es) |
CO (1) | CO2018005141A2 (es) |
CY (3) | CY1123042T1 (es) |
DK (3) | DK3628331T3 (es) |
EA (1) | EA037716B1 (es) |
ES (3) | ES2783855T3 (es) |
GE (1) | GEP20207157B (es) |
HR (3) | HRP20211598T1 (es) |
HU (3) | HUE056260T2 (es) |
IL (1) | IL259329B (es) |
LT (3) | LT3620176T (es) |
MA (3) | MA43256B1 (es) |
MD (3) | MD3628331T2 (es) |
ME (1) | ME03778B (es) |
MX (1) | MX2018005977A (es) |
MY (1) | MY186229A (es) |
PE (1) | PE20181488A1 (es) |
PH (1) | PH12018501022B1 (es) |
PL (3) | PL3628331T3 (es) |
PT (3) | PT3620176T (es) |
RS (3) | RS60171B1 (es) |
SA (1) | SA518391570B1 (es) |
SG (2) | SG10201912093YA (es) |
SI (3) | SI3628331T1 (es) |
TW (1) | TWI731891B (es) |
UA (1) | UA125019C2 (es) |
WO (1) | WO2017085004A1 (es) |
ZA (1) | ZA201803168B (es) |
Families Citing this family (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
MX2019012931A (es) * | 2017-05-11 | 2020-01-20 | Chiesi Farm Spa | Proceso para preparar una formulacion de polvo seco que comprende un anticolinergico, un corticosteroide y un beta-adrenergico. |
CN110612095A (zh) * | 2017-05-11 | 2019-12-24 | 奇斯药制品公司 | 制备包含抗胆碱能药、皮质类固醇和β-肾上腺素能药的干粉制剂的方法 |
US11433063B1 (en) | 2019-03-12 | 2022-09-06 | Belhaven Biopharma, Inc. | Intranasal composition of pharmaceutical countermeasures for chemical warfare nerve agents and accidental exposure to organophosphate pesticides |
BR112021019077A2 (pt) * | 2019-03-27 | 2021-11-30 | Kemin Ind Inc | Métodos para fabricar um ou mais carboxilatos de metal e múltiplos carboxilatos de metal em uma única reação, e, carboxilato de metal |
CN112137957B (zh) * | 2019-06-26 | 2022-07-29 | 长风药业股份有限公司 | 一种药用吸入气雾剂及其制备方法 |
WO2021143785A1 (zh) * | 2020-01-15 | 2021-07-22 | 四川海思科制药有限公司 | 一种含茚达特罗的吸入气雾剂药物组合物及其制备方法 |
WO2022045995A1 (en) * | 2020-08-28 | 2022-03-03 | Arven Ilac Sanayi Ve Ticaret Anonim Sirketi | A process for the preparation of dry powder compositions for inhalation |
US20220304894A1 (en) * | 2021-03-24 | 2022-09-29 | Cmpd Licensing, Llc | Drug powderization within vials |
WO2023117967A1 (en) | 2021-12-21 | 2023-06-29 | Chiesi Farmaceutici S.P.A. | Dry powder formulations filled in an inhaler with improved resistance to humidity |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
PE20011227A1 (es) * | 2000-04-17 | 2002-01-07 | Chiesi Farma Spa | Formulaciones farmaceuticas para inhaladores de polvo seco en la forma de aglomerados duros |
GB0015043D0 (en) | 2000-06-21 | 2000-08-09 | Glaxo Group Ltd | Medicament dispenser |
ES2359576T5 (es) | 2002-07-31 | 2020-03-03 | Chiesi Farm Spa | Inhalador de polvo |
NZ600790A (en) * | 2009-12-23 | 2014-09-26 | Chiesi Farma Spa | Combination therapy for copd |
ES2663878T3 (es) * | 2012-12-06 | 2018-04-17 | Chiesi Farmaceutici S.P.A. | Compuestos que tienen actividad antagonista del receptor muscarínico y actividad agonista del receptor beta-2 adrenérgico |
EA030552B1 (ru) * | 2012-12-06 | 2018-08-31 | КЬЕЗИ ФАРМАЧЕУТИЧИ С.п.А. | Соединения, обладающие активностью антагонистов мускариновых рецепторов и агонистов бета2 адренергических рецепторов |
US9393202B2 (en) | 2013-04-26 | 2016-07-19 | Chiesi Farmaceutici S.P.A | Particle size reduction of an antimuscarinic compound |
LT3409270T (lt) * | 2013-07-11 | 2021-07-26 | Chiesi Farmaceutici S.P.A. | Sausų miltelių kompozicija, apimanti anticholinerginį agentą, kortikosteroidą ir beta adrenerginį agentą, skirta vartoti įkvepiant |
-
2016
- 2016-11-14 MY MYPI2018000704A patent/MY186229A/en unknown
- 2016-11-14 WO PCT/EP2016/077558 patent/WO2017085004A1/en active Application Filing
- 2016-11-14 SI SI201631349T patent/SI3628331T1/sl unknown
- 2016-11-14 SG SG10201912093YA patent/SG10201912093YA/en unknown
- 2016-11-14 MA MA43256A patent/MA43256B1/fr unknown
- 2016-11-14 AR ARP160103473A patent/AR106688A1/es unknown
- 2016-11-14 DK DK19205936.8T patent/DK3628331T3/da active
- 2016-11-14 HU HUE19205936A patent/HUE056260T2/hu unknown
- 2016-11-14 DK DK16801982.6T patent/DK3377108T3/da active
- 2016-11-14 PE PE2018000973A patent/PE20181488A1/es unknown
- 2016-11-14 MX MX2018005977A patent/MX2018005977A/es unknown
- 2016-11-14 EA EA201890966A patent/EA037716B1/ru unknown
- 2016-11-14 PL PL19205936T patent/PL3628331T3/pl unknown
- 2016-11-14 EP EP19205980.6A patent/EP3620176B1/en active Active
- 2016-11-14 HU HUE16801982A patent/HUE049751T2/hu unknown
- 2016-11-14 UA UAA201805271A patent/UA125019C2/uk unknown
- 2016-11-14 PL PL19205980T patent/PL3620176T3/pl unknown
- 2016-11-14 MD MDE20200898T patent/MD3628331T2/ro unknown
- 2016-11-14 CA CA3005290A patent/CA3005290A1/en active Pending
- 2016-11-14 ES ES16801982T patent/ES2783855T3/es active Active
- 2016-11-14 LT LTEP19205980.6T patent/LT3620176T/lt unknown
- 2016-11-14 ES ES19205936T patent/ES2895687T3/es active Active
- 2016-11-14 ME MEP-2020-80A patent/ME03778B/me unknown
- 2016-11-14 RS RS20200440A patent/RS60171B1/sr unknown
- 2016-11-14 LT LTEP16801982.6T patent/LT3377108T/lt unknown
- 2016-11-14 RS RS20211283A patent/RS62506B1/sr unknown
- 2016-11-14 MD MDE20180917T patent/MD3377108T2/ro unknown
- 2016-11-14 HR HRP20211598TT patent/HRP20211598T1/hr unknown
- 2016-11-14 HR HRP20211600TT patent/HRP20211600T1/hr unknown
- 2016-11-14 AU AU2016356858A patent/AU2016356858B2/en active Active
- 2016-11-14 EP EP19205936.8A patent/EP3628331B1/en active Active
- 2016-11-14 KR KR1020187013286A patent/KR20180082443A/ko unknown
- 2016-11-14 HU HUE19205980A patent/HUE056441T2/hu unknown
- 2016-11-14 RS RS20211196A patent/RS62404B1/sr unknown
- 2016-11-14 EP EP16801982.6A patent/EP3377108B1/en active Active
- 2016-11-14 MA MA50488A patent/MA50488B1/fr unknown
- 2016-11-14 PT PT192059806T patent/PT3620176T/pt unknown
- 2016-11-14 DK DK19205980.6T patent/DK3620176T3/da active
- 2016-11-14 JP JP2018524832A patent/JP6963548B2/ja active Active
- 2016-11-14 PT PT168019826T patent/PT3377108T/pt unknown
- 2016-11-14 LT LTEP19205936.8T patent/LT3628331T/lt unknown
- 2016-11-14 PT PT192059368T patent/PT3628331T/pt unknown
- 2016-11-14 MD MDE20200899T patent/MD3620176T2/ro unknown
- 2016-11-14 ES ES19205980T patent/ES2891073T3/es active Active
- 2016-11-14 TW TW105137048A patent/TWI731891B/zh active
- 2016-11-14 MA MA50487A patent/MA50487B1/fr unknown
- 2016-11-14 SG SG11201804050QA patent/SG11201804050QA/en unknown
- 2016-11-14 SI SI201631331T patent/SI3620176T1/sl unknown
- 2016-11-14 CN CN201680066801.5A patent/CN108289962B/zh active Active
- 2016-11-14 SI SI201630682T patent/SI3377108T1/sl unknown
- 2016-11-14 GE GEAP201614783A patent/GEP20207157B/en unknown
- 2016-11-14 PL PL16801982T patent/PL3377108T3/pl unknown
- 2016-11-15 US US15/351,562 patent/US10086004B2/en active Active
-
2018
- 2018-05-14 SA SA518391570A patent/SA518391570B1/ar unknown
- 2018-05-14 IL IL259329A patent/IL259329B/en active IP Right Grant
- 2018-05-14 ZA ZA2018/03168A patent/ZA201803168B/en unknown
- 2018-05-14 CL CL2018001298A patent/CL2018001298A1/es unknown
- 2018-05-15 PH PH12018501022A patent/PH12018501022B1/en unknown
- 2018-05-16 CO CONC2018/0005141A patent/CO2018005141A2/es unknown
- 2018-08-27 US US16/113,026 patent/US10772896B2/en active Active
-
2020
- 2020-04-01 HR HRP20200537TT patent/HRP20200537T1/hr unknown
- 2020-04-06 CY CY20201100319T patent/CY1123042T1/el unknown
- 2020-08-07 US US16/987,695 patent/US10966991B2/en active Active
-
2021
- 2021-02-24 US US17/184,181 patent/US11628175B2/en active Active
- 2021-09-07 CY CY20211100793T patent/CY1124475T1/el unknown
- 2021-09-09 CY CY20211100797T patent/CY1124490T1/el unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CO2018005141A2 (es) | Proceso para preparar una formulación en polvo seco que comprende un anticolinérgico, un corticosteroide y un beta-adrenérgico | |
CO2018005139A2 (es) | Proceso para preparar una formulación en polvo seco que comprende un anticolinérgico, un corticosteroide y un beta-adrenérgico | |
TH1601000099A (th) | สูตรผสมผงแห้งที่ประกอบรวมด้วยแอนติโคลิเนอร์จิก, คอร์ติโคสเตียรอยด์ และเบตา-แอดรีเนอร์จิกสำหรับการให้โดยการสูด |